Related Experiment Video
Updated: Mar 10, 2026
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
LeiCNS-PK3.2: A physiologically based pharmacokinetic model framework for predicting intracellular concentrations of
Ming Sun1, Martijn L Manson1, Tingjie Guo1
1Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, Netherlands.
Background:
Effective treatment of viral infections in the central nervous system (CNS) requires adequate nucleoside analogs exposure and conversion into phosphorylated metabolites (TP) in brain cells.
Aim:
To develop a CNS PBPK model (LeiCNS-PK3.2) that incorporates active brain cell membrane transport and brain intracellular fluid (brainICF) metabolism to predict and understand target site pharmacokinetics (PK), brainICF active triphosphate (TP) metabolites, and effects of antiviral drugs.
Method:
LeiCNS-PK3.0 was extended with a brain cell membrane asymmetry factor (AF) using rat-derived Kp,uu,cell values. Intracellular conversion of acyclovir and ganciclovir into TPs was modelled using in vitro kinetic parameters. LeiCNS-PK3.2 was validated on published rat and human plasma, brain extracellular fluid (brainECF), and cerebrospinal fluid (CSF) data. Simulated PK profiles for parent drug standard dosing regimens (acyclovir 10 mg/kg t.i.d.; ganciclovir 5 mg/kg b.i.d.) were compared to parent-drug profiles in brainECF, and TP metabolite in brainICF. Sensitivity analyses were performed on CNS physiological parameters and Kp,uu,cell values.
Results:
LeiCNS-PK3.2 accurately recaptured the observed data (<2-fold error range). Simulated brainECF parent drug concentrations often remained below reported IC50 values, whereas brainICF TPs had smaller AUCs and longer time to equilibrium compared to acyclovir/ganciclovir in brainECF. Simulated pathological variations during CNS infection showed minimal impact on brainICF TP exposure, with proportional shifts in brainICF TP concentrations when varying Kp,uu,cell. CONCLUSIONS: LeiCNS-PK3.2 can predict CNS target-site exposure of TPs and demonstrates that brainECF acyclovir/ganciclovir concentrations are distinct from brainICF TP levels. It may support intracellular PK/PD target determination to optimize dosing strategies for CNS viral infections.
More Related Videos
10:44Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model